Pharmacokinetics and targeted delivery of proteins and genes

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 91-97

  Hashida, Mitsuru ^a   Mahato, Ram I ^a   Kawabata, Kenji ^a   Miyao, Takenori ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cationic liposomes; Chemical modification; Pharmacokinetics; Protein and gene targeting; Receptor mediated endocytosis

Indexed keywords

BOVINE SERUM ALBUMIN; CARBOXYMETHYLDEXTRAN; CATION; DIETHYLAMINOETHYLDEXTRAN; IMMUNOGLOBULIN G; INDIUM 111; LIPOSOME; LYSOZYME; MACROGOL; OLIGONUCLEOTIDE; PHOSPHORUS 32; PLASMID DNA; PROTEIN; REAGENT; RECEPTOR; SCAVENGER RECEPTOR; SOYBEAN TRYPSIN INHIBITOR; SUCCINIC ANHYDRIDE; SUPEROXIDE DISMUTASE DERIVATIVE; UNCLASSIFIED DRUG; URATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD; CHEMICAL MODIFICATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; ELECTRICITY; ENDOCYTOSIS; GENE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ISCHEMIA; LIVER; LIVER ISCHEMIA; MACROMOLECULE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 0030222224     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01360-0     Document Type: Conference Paper

References (21)

1. [1] H. Sezaki and M. Hashida, Macromolecule-drug conjugates in targeted cancer chemotherapy, CRC Crit. Rev. Ther. Drug Carrier Syst. 1 (1984) 1-38.
2. [2] M. Hashida and Y. Takakura, Pharmacokinetics in design of polymeric drug delivery systems, J. Control. Release 31 (1994) 163-171.
3. [3] M. Hashida, Y. Takakura and H. Sezaki, Control of disposition characteristics of proteins by chemical modification with carbohydrates, in: B.-K. Kim, E.B. Lee, C.-K. Kim and Y.N. Han (Eds.), Advances in New Drug Development, The Pharmaceutical Society of Korea, Seoul, 1991, pp. 741-749.
4. [4] Y. Takakura, T. Fujita, M. Hashida and H. Sezaki, Disposition characteristics of macromolecules in tumor-bearing mice, Pharm. Res. 7 (1990) 339-346.
5. [5] K. Nishida, K. Mihara, T. Takino, S. Nakane, Y. Takakura, N. Hashida and H. Sezaki, Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver, Pharm. Res. 8 (1991) 437-444.
6. [6] Y. Takakura, T. Fujita, H. Furitsu, M. Nishikawa, H. Sezaki and M. Hashida, Pharmacokinetics of succinylated proteins and dextran sulfate in mice: implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors, Int. J. Pharm. 105 (1994) 19-29.
7. [7] H. Imoto, Y. Sakamura, K. Ohkouchi, R. Atsumi, Y. Takakura, H. Sezaki and M. Hashida, Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation, Cancer Res. 52 (1992) 4396-4401.
8. [8] Y. Lee, C. Stowell and M. Krantz, 2-Imino-2-methoxyethyl 1-thioglycoside: new reagents for attaching sugars to proteins, Biochemistry 15 (1976) 3956-3963.
9. [9] M. Hashida, M. Nishikawa, F. Yamashita and Y. Takakura, Targeting delivery of protein drugs by chemical modification, Drug Dev. Ind. Pharm. 20 (1994) 581-590.
10. [10] K. Kawabata Y. Takakura and M. Hashida, The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake, Pharm. Res., 12 (1995) 825-830.
11. [11] T. Miyao, Y. Takakura, T. Akiyama, F. Yoneda, H. Sezaki and M. Hashida, Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice, Antisense Res. Dev. 5 (1995) 115-121.
12. [12] D. Hnatowich, W.W. Layne and R.L. Childs, The preparation and labeling of DTPA-coupled albumin, Int. J. Appl. Radiat. Isot. 12 (1982) 327-332.
13. [13] Y. Takakura, A. Takagi, M. Hashida and H. Sezaki, Disposition and tumor localization of mitomycin C-dextran conjugates in mice, Pharm. Res. 4 (1987) 293-300.
14. [14] M. Nishikawa, Y. Ohtsubo, J. Ohno, T. Fujita, Y. Koyama, F. Yamashita, M. Hashida and H. Sezaki, Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice, Int. J. Pharm. 85 (1993) 75-85.
15. [15] L.W. Seymour, Soluble polymers for lectin-mediated drug targeting, Adv. Drug Delivery Rev. 14 (1994) 89-111.
16. [16] T. Fujita, H. Furitsu, M. Nishikawa, Y. Takakura, H. Sezaki and M. Hashida, Therapeutic effect of superoxide dismutase derivatives modified with mono-or polysaccharides on hepatic injury induced by ischemia/reperfusion, Biochem. Biophys. Res. Commun. 189 (1992) 191-196.
17. [17] K. Mihara, Y. Oka, K. Sawai, Y. Takakura and M. Hashida, Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol, J. Drug Targeting 2 (1994) 317-321.
18. [18] Y. Takakura, S. Masuda, H. Tokuda, M. Nishikawa and M. Hashida, Targeted delivery of superoxide dismutase to macrophages via mannose-receptor-mediated mechanism, Biochem. Pharmacol. 47 (1994) 853-858.
19. [19] Y. Takakura, K. Mihara and M. Hashida, Control of the disposition profiles of proteins in the kidney via chemical modification, J. Control. Release 28 (1994) 111-119.
20. [20] R.I. Mahato, K. Kawabata, T. Nomura, Y. Takakura and M. Hashida, Physicochemical and pharmacokinetic characteristics of plasmid DNA complexed with cationic liposomes, J. Pharm. Sci. 84 (1995) 1267-1271.
21. [21] T. Miyao, Y. Takakura and M. Hashida, Stability and in vivo disposition characteristics of oligonucleotides and oligonucleotides conjugate with macromolecules, Proc. Intl. Symp. Control. Rel. Bioact. Mater. 20 (1993) 492-493.